BG63209B1 - Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост - Google Patents

Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост Download PDF

Info

Publication number
BG63209B1
BG63209B1 BG102280A BG10228098A BG63209B1 BG 63209 B1 BG63209 B1 BG 63209B1 BG 102280 A BG102280 A BG 102280A BG 10228098 A BG10228098 A BG 10228098A BG 63209 B1 BG63209 B1 BG 63209B1
Authority
BG
Bulgaria
Prior art keywords
fragments
seq
nom
amino acids
homologs
Prior art date
Application number
BG102280A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102280A (en
Inventor
Ivar Loennroth
Stefan Lange
Eva Johansson
Eva Jennische
Christina Loennroth
Original Assignee
Rural Patent Svenska Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rural Patent Svenska Ab filed Critical Rural Patent Svenska Ab
Publication of BG102280A publication Critical patent/BG102280A/xx
Publication of BG63209B1 publication Critical patent/BG63209B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
BG102280A 1995-08-24 1998-02-24 Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост BG63209B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502936A SE508609C2 (sv) 1995-08-24 1995-08-24 Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
PCT/SE1996/001049 WO1997008202A1 (en) 1995-08-24 1996-08-23 Antisecretory factor peptides regulating pathological permeability changes

Publications (2)

Publication Number Publication Date
BG102280A BG102280A (en) 1999-04-30
BG63209B1 true BG63209B1 (bg) 2001-06-29

Family

ID=20399269

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102280A BG63209B1 (bg) 1995-08-24 1998-02-24 Пептиди на антисекреторен фактор регулиращи паталогичните промени на пропускливост

Country Status (29)

Country Link
US (2) US6344440B1 (ja)
EP (1) EP0851876B1 (ja)
JP (2) JP4040679B2 (ja)
KR (1) KR100552947B1 (ja)
CN (1) CN1171902C (ja)
AT (1) ATE270305T1 (ja)
AU (1) AU702589B2 (ja)
BG (1) BG63209B1 (ja)
BR (1) BR9610308A (ja)
CA (1) CA2230111C (ja)
CZ (1) CZ295444B6 (ja)
DE (2) DE851876T1 (ja)
DK (1) DK0851876T3 (ja)
EA (1) EA001201B1 (ja)
EE (1) EE04501B1 (ja)
ES (1) ES2118683T3 (ja)
HK (1) HK1018468A1 (ja)
HU (1) HU224971B1 (ja)
IL (1) IL123404A (ja)
NO (1) NO320560B1 (ja)
NZ (2) NZ316647A (ja)
PL (1) PL188530B1 (ja)
PT (1) PT851876E (ja)
RO (1) RO120197B1 (ja)
SE (1) SE508609C2 (ja)
SI (1) SI0851876T1 (ja)
SK (1) SK23698A3 (ja)
TR (1) TR199800304T1 (ja)
WO (1) WO1997008202A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
BRPI0710959B8 (pt) * 2006-04-27 2021-05-25 Lantmaennen As Faktor Ab uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
DK2040734T3 (da) 2006-04-27 2012-01-23 Lantmaannen As Faktor Ab Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
JP6999638B2 (ja) * 2016-07-18 2022-01-18 ラントメネン・メディカル・アーベー 抗分泌性因子１７
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065089A2 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted dehulled oat
CN112770644A (zh) * 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化小麦的可消耗产品
JP2023518790A (ja) 2020-03-26 2023-05-08 ラントメネン・ファンクショナル・フーズ・アーベー 身体活動時の回復を促進するための麦芽穀類を含む消費可能な製品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning

Also Published As

Publication number Publication date
PL188530B1 (pl) 2005-02-28
DK0851876T3 (da) 2004-10-25
CN1171902C (zh) 2004-10-20
HU224971B1 (en) 2006-04-28
JP4040679B2 (ja) 2008-01-30
WO1997008202A1 (en) 1997-03-06
IL123404A (en) 2005-07-25
HUP9900137A2 (hu) 1999-04-28
RO120197B1 (ro) 2005-10-28
HK1018468A1 (en) 1999-12-24
CZ52098A3 (cs) 1998-09-16
KR100552947B1 (ko) 2006-04-21
SK23698A3 (en) 1998-12-02
JP2008043331A (ja) 2008-02-28
ATE270305T1 (de) 2004-07-15
EA001201B1 (ru) 2000-12-25
NZ337380A (en) 2001-02-23
EA199800221A1 (ru) 1998-10-29
PL325114A1 (en) 1998-07-06
NZ316647A (en) 1999-10-28
NO980743D0 (no) 1998-02-23
EP0851876B1 (en) 2004-06-30
JPH11511972A (ja) 1999-10-19
SI0851876T1 (en) 2004-10-31
AU6893296A (en) 1997-03-19
DE851876T1 (de) 1998-11-12
ES2118683T1 (es) 1998-10-01
BR9610308A (pt) 1999-12-21
CA2230111A1 (en) 1997-03-06
EE9800055A (et) 1998-08-17
KR19990044110A (ko) 1999-06-25
AU702589B2 (en) 1999-02-25
US6344440B1 (en) 2002-02-05
CN1208420A (zh) 1999-02-17
BG102280A (en) 1999-04-30
ES2118683T3 (es) 2004-12-01
IL123404A0 (en) 1998-09-24
NO980743L (no) 1998-04-16
CA2230111C (en) 2012-10-30
US20020099016A1 (en) 2002-07-25
SE9502936L (sv) 1997-02-25
HUP9900137A3 (en) 1999-11-29
SE9502936D0 (sv) 1995-08-24
DE69632828T2 (de) 2005-07-14
EE04501B1 (et) 2005-06-15
SE508609C2 (sv) 1998-10-19
TR199800304T1 (xx) 1998-05-21
CZ295444B6 (cs) 2005-08-17
DE69632828D1 (de) 2004-08-05
NO320560B1 (no) 2005-12-19
EP0851876A1 (en) 1998-07-08
PT851876E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
JP2008043331A (ja) 病理学的浸透性の変化を調節する抗分泌性因子ペプチド
Johansson et al. Molecular Cloning and Expression of a Pituitary Gland Protein Modulating Intestinal Fluid Secretion (∗)
Brigstock et al. Purification and Characterization of Novel Heparin-binding Growth Factors in Uterine Secretory Fluids: IDENTIFICATION AS HEPARIN-REGULATED M r10, 000 FORMS OF CONNECTIVE TISSUE GROWTH FACTOR
Saruta et al. Expression and localization of chromogranin A gene and protein in human submandibular gland
JP2020007373A (ja) 抗肥満及び抗糖尿作用を有するペプチド及びその用途
NO332460B1 (no) Renset humant NOGO protein, fusjon- eller kimaert protein, isolert nukleinsyre, kloningsvektor, rekombinant celle, fremgangsmate for fremstilling av proteinet, samt anvendelse av proteinet for fremstilling av et medikament for behandling.
Kinoshita et al. Urine and plasma levels of uroguanylin and its molecular forms in renal diseases
JP2009254370A (ja) ヘパリン結合増殖因子（ｈｂｇｆ）ポリペプチド
Leberer et al. Molecular cloning and expression of cDNA encoding the 53,000-dalton glycoprotein of rabbit skeletal muscle sarcoplasmic reticulum
Johansson et al. Identification of an active site in the antisecretory factor protein
PT98805B (pt) Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Aunis et al. Chromogranins: current concepts: structural and functional aspects
Ingleton et al. Calcium‐sensing receptors and parathyroid hormone‐related protein in the caudal neurosecretory system of the flounder (Platichthys flesus)
JPH03172183A (ja) 脳因子発現系
PT99995B (pt) Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-6)
CN109106943A (zh) 抗癫痫的毒素Martentoxin及其应用
Nock Development of an Enzyme Immunoassay and Cellular Function Assays to Probe the Function of Teneurin C-terminal Associated Peptide (TCAP).
JPS6229981A (ja) サルコフア−ガ・レクチンの構造遺伝子
Iguchi et al. Expression of secretin in porcine and rat central nervous system
AU4440302A (en) Heparin-binding growth factor (HBGF) polypeptides